|Year : 2021 | Volume
| Issue : 1 | Page : 38-41
A report on incidence of COVID-19 among febrile patients attending a malaria clinic
Subhasish Kamal Guha1, Malabika Biswas2, Bishal Gupta2, Alisha Acharya2, Supriya Halder3, Bibhuti Saha1, Moytrey Chatterjee3, Pratip Kumar Kundu4, Ardhendu Kumar Maji3
1 Department of Tropical Medicine, Calcutta School of Tropical Medicine, Kolkata, West Bengal, India
2 Department of Microbiology, Calcutta School of Tropical Medicine, Kolkata, West Bengal, India
3 Protozoology Unit, Department of Microbiology, Calcutta School of Tropical Medicine, Kolkata, West Bengal, India
4 Director and Department of Microbiology, Calcutta School of Tropical Medicine, Kolkata, West Bengal, India
|Date of Submission||24-Sep-2020|
|Date of Decision||24-Dec-2020|
|Date of Acceptance||03-Mar-2021|
|Date of Web Publication||13-May-2021|
Subhasish Kamal Guha
Department of Tropical Medicine, Calcutta School of Tropical Medicine, Kolkata, West Bengal
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Context: Screening for malaria and coronavirus disease (COVID-19) in all patients with acute febrile illness is necessary in malaria-endemic areas to reduce malaria-related mortality and to prevent the transmission of COVID-19 by isolation.
Aims: A pilot study was undertaken to determine the incidence of SARS-CoV-2 infection among febrile patients attending a malaria clinic.
Subjects and Methods: All patients were tested for malaria parasite by examining thick and thin blood smears as well as by rapid malaria antigen tests. COVID-19 was detected by rapid antigen test and reverse transcriptase–polymerase chain reaction in patients agreeing to undergo the test.
Results: Out of 262 patients examined, 66 (25.19%) were positive for Plasmodium vivax, 45 (17.17%) for Plasmodium falciparum (Pf) with a slide positivity rate of 42.40%, and Pf% of 40.50%. Only 29 patients consented for COVID-19 testing along with malaria; of them, 3 (10.34%) were positive for COVID-19 alone and 2 (6.89%) were positive for both COVID-19 and P. vivax with an incidence of 17.24%. A maximum number of patients (196) did not examine for COVID-19 as they did not agree to do the test.
Conclusion: Diagnosis of COVID-19 among three patients (10.34%) is significant both in terms of identification of cases and to isolate them for preventing transmission in the community. Detection of COVID-19 along with malaria is equally important for their proper management.
Keywords: COVID-19, COVID-malaria coinfection, India, Plasmodium falciparum, Plasmodium vivax
|How to cite this article:|
Guha SK, Biswas M, Gupta B, Acharya A, Halder S, Saha B, Chatterjee M, Kundu PK, Maji AK. A report on incidence of COVID-19 among febrile patients attending a malaria clinic. Trop Parasitol 2021;11:38-41
|How to cite this URL:|
Guha SK, Biswas M, Gupta B, Acharya A, Halder S, Saha B, Chatterjee M, Kundu PK, Maji AK. A report on incidence of COVID-19 among febrile patients attending a malaria clinic. Trop Parasitol [serial online] 2021 [cited 2022 Aug 15];11:38-41. Available from: https://www.tropicalparasitology.org/text.asp?2021/11/1/38/315924
| Introduction|| |
The coronavirus disease (COVID-19) caused by SARS-CoV-2 is now pandemic throughout the world. This has imposed an additional burden to the health-care delivery system and emerged as a global challenge for management of other prevailing infectious and communicable diseases including tuberculosis, malaria, and AIDS. About 50% of the world population is at risk of both malaria and COVID-19., In 2019, a total of 338,494 cases and 77 deaths due to malaria have been reported from India. Malaria endemic countries are facing the daunting task of diagnosis of these diseases and differentiation from COVID-19 disease. COVID-19 shows some symptoms similar to that of malaria (fever, headache, difficulty in breathing, and body ache). COVID-19-positive individuals may be symptomatic or asymptomatic but transmitting the infections to their close contacts., Although the nature of fever varies from disease to disease, it is very difficult to differentiate clinically at the time of initial clinical evaluation. Hence, proper diagnosis of malaria and COVID-19 is of utmost importance to reduce mortality. Hence, there is a need to differentiate between malaria and COVID-19 among acute febrile patients in malaria-endemic countries like India where malaria is seasonal and most prevalent during June to November due to high humidity and warm environment. The situation is complicated by COVID-19 infection this year. Public health experts are of the view that COVID-19 will peak during August–December that coincides with high malaria transmission season. A pilot study was undertaken to determine the incidence of COVID-19 infection among the acute febrile patients attending the Malaria Clinic attached with Calcutta School of Tropical Medicine, India.
| Subjects and Methods|| |
The present study was conducted from August 29 to September 12, 2020. The Malaria Clinic of the School of Tropical Medicine is engaged in the diagnosis and treatment of malaria routinely and draws patients from surrounding areas. All febrile patients attending the clinic were examined clinically and Giemsa-stained thick and thin blood smears were checked microscopically for malaria parasite, in addition to rapid malaria antigen testing using a dual-antigen test kit for malaria supplied by the National Vector Borne Disease Control Programme (NVBDCP). All clinic attendees were counseled and advised for COVID-19 testing along with malaria, but only a few of them (29) agreed to do so. Both nasopharyngeal and oropharyngeal swabs were taken. Nasopharyngeal swab samples were examined for SARS-CoV-2 antigen using rapid antigen test (RAT) (Standard Q COVID-19 Ag test kit made by SD Biosensor Healthcare Pvt. Ltd., India) as per manufacturer's instruction. As per guidelines formulated by the Indian Council of Medical Research (ICMR), those positives by RAT were declared as COVID-19 positive. Samples negative by RAT were tested by reverse transcriptase–polymerase chain reaction (RT-PCR) for detection of SARS-CoV-2 viral RNA by targeting E_Sarbeco gene and HKUORF1bnsp genes (ICMR, NIV, Pune). Both RAT and RT-PCR for detection of COVID-19 infection were done at the Microbiology Department of the Calcutta School of Tropical Medicine.
Malaria patients were treated according to diagnosed parasite species: chloroquine (CQ) plus primaquine (PQ) for Plasmodium vivax and artesunate (AS) plus sulfadoxine-pyrimethamine (SP) with PQ for Plasmodium falciparum (Pf) were prescribed as per NVBDCP guideline of India. COVID-19 patients were referred to a nearby dedicated COVID hospital for their appropriate inpatient management or home isolation.
This was an observational study. The data presented in this manuscript were generated from routine service to the patients. No clinical or therapeutic data of any patients are included in this manuscript. Verbal informed consent was obtained from all febrile patients attended for diagnosis of malaria before the interview and requested for COVID-19 testing. Those, who consented, were tested for COVID-19 along with malaria. The appropriate permission for publication of the data was obtained from the head of the institute.
| Results|| |
During the study period, a total of 262 patients attended the malaria clinic. All of them were examined for malaria, but only 29 (11.06%) consented for COVID-19 testing. Out of the 233 patients examined only for malaria, P. vivax was detected in 61 and Pf in 42 patients with a slide positivity rate (SPR) of 44.20% and Pf% of 40.80%. Among 29 patients tested for both malaria and COVID-19, P. vivax was detected in 5 and Pf in 3 patients. Three were positive for COVID-19 alone and two patients were coinfected with COVID-19 and P. vivax with an incidence of 17.24%. The overall SPR for malaria was 42.40% with Pf% of 40.50% [Table 1]. The COVID-19 patients were referred to COVID-19 hospital immediately for proper management. Both the coinfected cases opted for home isolation with appropriate advice by the health authority along with CQ and PQ in prescribed dose. The most important aspect was that the total attendance of the malaria clinic was dropped to one-third in respect to the same period of the previous year [Table 2].
|Table 1: Febrile patients attending the Malaria Clinic of School of Tropical Medicine for diagnosis of malaria during the study period and the observed pattern of malaria and COVID-19 infection (n=262)|
Click here to view
|Table 2: The decline in attendance of acute febrile patients (from March to August) during 2019 and 2020 at the malaria clinic|
Click here to view
| Discussion|| |
Detection of SARS-CoV-2 infection either alone or along with malaria among acutely ill febrile patients attending for malaria diagnosis is alarming from the public health perspective. In the present study, nearly 90% of patients attending the malaria clinic did not agree to take the COVID-19 test. This high refusal rate denotes that a significant proportion of patients with acute febrile illness are not being tested for COVID-19 diagnosis. The reason may be lack of awareness or fear of getting infected from COVID-19 testing laboratory or stigmatization with COVID-19 diagnosis. It is possible that some of them might be carrying the virus and staying with their family without self-isolation. Similarly, a large proportion of patients attending for COVID-19 diagnosis are not being examined for malaria during the pandemic. The COVID-19 patients might also be infected with malaria. Fever is common to both malaria and COVID-19 infection. In this pilot study, two patients had coinfection of COVID-19 and P. vivax malaria. Unless looked for specifically, one of the infections may remain undiagnosed. At present, negative febrile patients tested for COVID-19 or malaria alone are advised to back home. In fact, some of the malaria negative cases have COVID-19 infection, as observed in the present study. Such cases have the potential to transmit up to 3.58 susceptible individuals. On the other hand, untreated malaria cases remained as a source of transmission and deaths globally.,,
Although the modes of transmission of the diseases are different, such undiagnosed cases will play an important role in transmitting the diseases in the community., The presence of undiagnosed coinfection will worsen the clinical outcome as well.
Of note, patient attendance to the malaria clinic has declined sharply this year as compared to previous years [Table 2]. This indicates that some of the febrile patients are not attending for malaria diagnosis and treatment. Such cases might pose serious community transmission.
Coinfection of P. vivax malaria and COVID-19 was first reported from Qatar. There are few more such coinfection reports from Delhi and Mumbai, India.,,
Rapid diagnostic kits for malaria diagnosis and antimalarial drugs are readily available at each point of care including remote peripheral sites. This should also be made available in all COVID-19 hospitals and care facilities. An enhanced sensitization of the clinicians about COVID-19 and malaria coinfections and their management will reduce mortality by proper treatment with effective antimalarial drugs through appropriate referrals. Management of COVID-19 infection will obviously be as per current country and state guidelines.
Coinfection with malaria may also modify the clinical features of COVID-19. Malaria can induce a cytokine storm and pro-coagulant state similar to that seen in severe COVID-19. Consequently, coinfections with Plasmodium spp. and SARS-CoV-2 could result in substantially worse outcomes than mono-infections with either pathogen, and could shift the age pattern of severe COVID-19 to younger age groups.
India is having a policy of using hydroxychloroquine as primary chemoprophylaxis against COVID-19 infection among health-care workers as well as other frontline workers and asymptomatic, direct-contact family members. Hydroxychloroquine is also used for the treatment of mild patients with comorbidity and moderate cases of COVID-19 in India. Hence, it is expected to be equally effective against P. vivax coinfection as P. vivax in India is sensitive to it. Hence, Artemisinin combination therapy (ACT) (AS + SP) should be used for coinfection of COVID-19 with Pf coinfection.
Coinfection of COVID-19 with other viral and bacterial diseases like dengue, chikungunya, leptospirosis, enteric fever is also been reported. Such cases should be screened at the same point of testing, particularly in endemic areas.
| Conclusions|| |
A significant proportion of the febrile patients were unwilling for COVID-19 testing which requires urgent addressal through public health education. The seasonal outbreak of dengue, chikungunya, leptospirosis, and enteric fever during monsoon should also be considered in all COVID-19 patients for appropriate antimicrobial therapy and better clinical outcome. Hence, urgent research is needed in studying the impact of seasonal common infectious diseases on the natural history, clinical presentation, and mortality among COVID-19 patients.
We would like to acknowledge the Director, Calcutta School of Tropical Medicine, for his kind permission for publication of this article. We are thankful to the patients for their kind cooperation.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Hogan AB, Jewell BL, Sherrard-Smith E, Vesga JF, Watson OJ, Whittaker C, et al
. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: A modelling study. Lancet Glob Health 2020;8:e1132-41.
Nishiura H, Kobayashi T, Yang Y, Hayashi K, Miyama T, Kinoshita R, et al
. The rate of under ascertainment of novel coronavirus (2019-nCoV) infection: Estimation using Japanese Passengers data on evacuation flights. J Clin Med 2020;9:419.
Chourasia MK, Raghavendra K, Bhatt RM, Swain DK, Meshram HM, Meshram JK, et al
. Additional burden of asymptomatic and sub-patent malaria infections during low transmission season in forested tribal villages in Chhattisgarh, India. Malar J 2017;16:320.
Saha P, Ganguly S, Dutta S, Kundu PK, Bera DK, Basu N, et al.
Impact of artemisinin-based combination therapy on falciparum malaria in urban Kolkata: A clinic-based report. Jpn J Infect Dis 2015;68:321-3.
Shah PV. Prediction of the peak, effect of intervention, and total infected by COVID-19 in India. Disaster Med Public Health Prep 2020;9:1-11.
Chanda-Kapata P, Kapata N, Zumla A. COVID-19 and malaria: A symptom screening challenge for malaria endemic countries. Int J Infect Dis 2020;94:151-3.
Chen TM, Rui J, Wang QP, Zhao ZY, Cui JA, Yin L. A mathematical model for simulating the phase-based transmissibility of a novel coronavirus. Infect Dis Poverty 2020;9:24.
Challenger JD, Gonçalves BP, Bradley J, Bruxvoort K, Tiono AB, Drakeley C, et al
. How delayed and non-adherent treatment contribute to onward transmission of malaria: A modelling study. BMJ Glob Health 2019;4:e001856.
Chen I, Clarke SE, Gosling R, Hamainza B, Killeen G, Magill A, et al
. “Asymptomatic” malaria: A chronic and debilitating infection that should be treated. PLoS Med 2016;13:e1001942.
Sardar S, Sharma R, Alyamani TY, Aboukamar M. COVID-19 and Plasmodium vivax
malaria co-infection. IDCases 2020;21:e00879.
Kishore R, Dhakad S, Arif N, Dar L, Mirdha BR, Aggarwal R, et al
. COVID-19: Possible cause of induction of relapse of Plasmodium vivax
Infection. Indian J Pediatr 2020;87:751-2.
Ray M, Vazifdar A, Shivaprakash S. Co-infection with malaria and coronavirus disease-2019. J Glob Infect Dis 2020;12:162-3.
Panda AK, Tripathy R, Das BK. Plasmodium falciparum
infection may protect a population from severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis 2020;222:1570-1.
Nguyen T, Duong Bang D, Wolff A. 2019 novel coronavirus disease (COVID-19): Paving the road for rapid detection and point-of-care diagnostics. Micromachines (Basel) 2020;11:E306.
Gutman JR, Lucchi NW, Cantey PT, Steinhardt LC, Samuels AM, Kamb ML, et al
. Malaria and parasitic neglected tropical diseases: Potential syndemics with COVID-19? Am J Trop Med Hyg 2020;103:572-7.
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020;14:241-6.
Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, et al
. Co-infections of SARS-CoV2 with multiple common respiratory pathogens in infected patients. Sci China Life Sci 2020;63:606-9.
[Table 1], [Table 2]
|This article has been cited by|
||Co-Infection with Plasmodium vivax and COVID-19 in Thailand
| ||Parat Boonyarangka, Kittijarankon Phontham, Sabaithip Sriwichai, Kamonporn Poramathikul, Krit Harncharoenkul, Worachet Kuntawunginn, Napat Maneesrikhum, Sarayouth Srisawath, Chanida Seenuan, Chattakorn Thanyakait, Kanjana Inkabajan, Suda Pludpiem, Kingkan Pidtana, Samandra Demons, Brian Vesely, Mariusz Wojnarski, John S. Griesenbeck, Michele Spring |
| ||Tropical Medicine and Infectious Disease. 2022; 7(8): 145 |
|[Pubmed] | [DOI]|